RxDoctor Payments Data

Kavitha Tellakula, MD

Family Medicine · Alpharetta, GANPI 1952577850

Payments from drug & device makers

$8,119in general payments, 2019–2025

Across 397 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • AstraZeneca$996
  • Novo Nordisk$771
  • Lilly USA, LLC$735
  • AbbVie$735
  • Takeda Pharmaceuticals U.S.A., Inc.$469
  • plus $3K from 34 others

What the payments were for

  • Consulting fees$1,20015%
  • Food & beverage$6,91885%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,119 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$49,560
Medicare patients
164
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$41,872
FarxigaDapagliflozin Propanediol37$32,396
ProliaDenosumab17$29,441
MounjaroTirzepatide26$27,502
Xigduo XrDapaglifloz Propaned/Metformin15$12,422
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,601
SynthroidLevothyroxine Sodium33$3,274
Rosuvastatin Calcium251$2,173
Gabapentin53$1,367
Ibandronate Sodium28$1,347
Omega-3 Acid Ethyl Esters16$1,331
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$1,292
Atorvastatin Calcium236$1,251
Levothyroxine Sodium133$1,236
Diclofenac Sodium23$887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$771$41,87231 claims
AstraZenecaFarxiga$996$32,39637 claims
AmgenProlia$456$29,44117 claims
Lilly USA, LLCMounjaro$735$27,50226 claims
GSKTrelegy Ellipta$223$9,60113 claims
AbbVieSynthroid$735$3,27433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →